A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Ann L SharpleyClare WilliamsAdele A HolderBeata R GodlewskaNisha SinghMilensu ShanyindeOrla MacDonaldPhilip J CowenPublished in: Psychopharmacology (2020)
Trial Registry: www.clinicaltrials.gov , Identifier: NCT03013400.